Business
Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults
Pendopharm, a division of Pharmascience Inc., announced today that Health Canada has granted market authorization for Yorvipath® (palopegteriparatide injection), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of chronic hypoparathyroidism in adults. Yorvipath®, was developed by Ascendis Pharma A/S (NASDAQ: ASND) ("Ascendis").
About this update from Ascendis Pharma A/s
[{"type":"text","content":"MONTREAL, Feb. 6, 2026 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that Health Canada has granted market authorization for Yorvipath® (palopegteriparatide injection), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of chronic hypoparathyroidism in adults. Yorvipath®, was developed by Ascendis Pharma A/S (NASDAQ: ASND) ("Ascendis").","length":397,"tagName":"p"},{"type":"image","alt":"Pendopharm Logo (CNW Group/Pendopharm)","displaySize":"","headline":null,"caption":"Pendopharm Logo (CNW Group/Pendopharm)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":138,"url":"https://media.zenfs.com/en/cnwgroup.com/cd44f7827857c1216b39613091f84031"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/VxEJoPUtVC8AKaXiAP8RGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI0MztjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/cd44f7827857c1216b39613091f84031","width":400,"height":138}},"href":"https://mma.prnewswire.com/media/2889067/Pendopharm_Pendopharm_Announces_the_Approval_of_Yorvipath_%C2%A0_palo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"This approval follows the exclusive distribution agreement signed in July 2024 between Pendopharm and Ascendis Pharma, under which Pendopharm is responsible for the regulatory approval and commercialization of Yorvipath® in Canada, which is already approved in the US, European Union, UK, Australia, Switzerland, Israel and Japan. It is also under regulatory review or in development in other global markets.","length":408,"tagName":"p"},{"type":"text","content":"Pendopharm is collaborating closely with key partners to support a smooth transition toward market availability and to support efforts aimed at achieving coverage through public and private drug plans.","length":201,"tagName":"p"},{"type":"text","content":"An Important Milestone for Canadian Patients","length":44,"tagName":"p"},{"type":"text","content":""Health Canada's approval of Yorvipath® marks a transformational moment for Canadians living with chronic hypoparathyroidism," said Dr. Aliya Khan, a leading Canadian hypoparathyroid expert and Clinical Professor of Medicine at McMaster University. "There has long been a need for new treatment options in Canada, and this product represents a step forward toward meeting...